Equities

Futura Medical PLC

FUM:LSE

Futura Medical PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)36.55
  • Today's Change-0.975 / -2.60%
  • Shares traded291.62k
  • 1 Year change-39.08%
  • Beta2.1316
Data delayed at least 20 minutes, as of Jul 02 2024 15:30 BST.
More ▼

Profile data is unavailable for this security.

About the company

Futura Medical plc is a United Kingdom-based pharmaceutical company. The Company is engaged in the development and sale of pharmaceutical and healthcare products. It is focused on developing a portfolio of products based on its transdermal DermaSys technology. The DermaSys is designed to deliver clinically proven medical treatments via the skin. DermaSys platform with penetration and permeation enhancer components tailored for each product to suit the specific therapeutic indication and desired speed of onset and duration of action. Such targeted delivery offers an optimized profile in terms of dose, onset time and duration of effect. The Company's products include MED3000 and TPR100. The Company's lead product, MED3000, is a topical gel formulation treatment for erectile dysfunction (ED) through an evaporative mode of action. The Company has conducted a Phase III study using MED3000 in ED. The Company is also developing CBD100, which is a topical cannabidiol formulation.

  • Revenue in GBP (TTM)3.10m
  • Net income in GBP-6.51m
  • Incorporated2001
  • Employees12.00
  • Location
    Futura Medical PLC40 Occam RoadGUILDFORD GU2 7YGUnited KingdomGBR
  • Phone+44 14 8368 5670Fax+44 14 8368 5671
  • Websitehttps://www.futuramedical.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Oxford Biodynamics PLC617.00k-11.11m23.11m45.0023.11m45.00
Incanthera PLC0.00-1.48m30.92m8.0030.92m8.00
Arecor Therapeutics PLC4.57m-8.55m36.75m50.0036.75m50.00
Sareum Holdings Plc0.00-4.26m48.58m5.0048.58m5.00
Poolbeg Pharma PLC0.00-3.93m64.75m8.0064.75m8.00
Faron Pharmaceuticals Oy0.00-26.22m97.82m34.0097.82m34.00
Scancell Holdings Plc0.00-11.32m103.24m51.00103.24m51.00
Futura Medical PLC3.10m-6.51m113.12m12.00113.12m12.00
hVIVO PLC56.04m16.12m183.36m274.00183.36m274.00
Avacta Group Plc23.25m-24.95m188.50m154.00188.50m154.00
4Basebio PLC506.00k-7.67m198.48m--198.48m--
Allergy Therapeutics plc53.26m-50.22m224.02m635.00224.02m635.00
Data as of Jul 02 2024. Currency figures normalised to Futura Medical PLC's reporting currency: UK Pound GBX

Institutional shareholders

59.39%Per cent of shares held by top holders
HolderShares% Held
Lombard Odier Asset Management (Europe) Ltd.as of 16 Jun 202368.25m22.64%
UBS Asset Management (UK) Ltd.as of 01 Apr 202433.46m11.10%
Janus Henderson Investors UK Ltd.as of 01 Apr 202426.56m8.81%
Lombard Odier Asset Management (USA) Corp.as of 01 Apr 202410.71m3.55%
Chelverton Asset Management Ltd.as of 31 Mar 20238.81m2.92%
Hargreaves Lansdown Asset Management Ltd.as of 01 Apr 20248.25m2.74%
Atlantis Investment Management Ltd. /Hong Kong/as of 21 Apr 20217.94m2.63%
Unicorn Asset Management Ltd.as of 01 Apr 20245.75m1.91%
Maitland Asset Management (Pty) Ltd.as of 01 Apr 20244.84m1.60%
Credit Suisse Asset Management (Schweiz) AGas of 01 Apr 20244.47m1.48%
More ▼
Data from 30 Jun 2023 - 03 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.